Skip to Content

Apellis Pharmaceuticals Inc APLS

Morningstar Rating
$68.51 +0.92 (1.36%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

APLS is trading at a 27% discount.
Price
$67.41
Fair Value
$93.11
Uncertainty
Extreme
1-Star Price
$391.37
5-Star Price
$61.72
Economic Moat
Jxmjz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APLS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$67.59
Day Range
$67.0268.73
52-Week Range
$19.8394.75
Bid/Ask
$68.48 / $68.51
Market Cap
$8.12 Bil
Volume/Avg
680,130 / 2.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
28.65
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
767

Comparables

Valuation

Metric
APLS
CRNX
ACLX
Price/Earnings (Normalized)
Price/Book Value
34.344.4211.79
Price/Sales
28.65420.7563.97
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
APLS
CRNX
ACLX
Quick Ratio
3.4414.002.76
Current Ratio
4.2914.232.84
Interest Coverage
−19.98−36.39
Quick Ratio
APLS
CRNX
ACLX

Profitability

Metric
APLS
CRNX
ACLX
Return on Assets (Normalized)
−57.78%−40.97%−19.97%
Return on Equity (Normalized)
−171.16%−46.50%−38.45%
Return on Invested Capital (Normalized)
−121.77%−47.26%−31.78%
Return on Assets
APLS
CRNX
ACLX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNddsk$552.7 Bil
VRTX
Vertex Pharmaceuticals IncKngnfz$110.2 Bil
REGN
Regeneron Pharmaceuticals IncGcbcdk$105.9 Bil
MRNA
Moderna IncHmlb$37.9 Bil
ARGX
argenx SE ADRHqblt$23.9 Bil
BNTX
BioNTech SE ADRKxx$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncCxbbhk$20.5 Bil
BMRN
Biomarin Pharmaceutical IncPdkvdb$16.9 Bil
RPRX
Royalty Pharma PLC Class ATxzzh$13.9 Bil
INCY
Incyte CorpKqpgyk$13.7 Bil

Sponsor Center